




Clinical Trials Appendix

PARIS: IPH.PA

NASDAQ: IPHA



Monalizumab (NKG2A mAb): HNSCC

Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 3 INTERLINK-1 NCT04590963	AstraZeneca	Recurrent or Metastatic HNSCC, 2L	600	Arm 1: • monalizumab + cetuximab Arm 2: • placebo + cetuximab	Primary endpoints: • OS Secondary endpoints: • PFS, ORR, DoR
Phase 1/2 IPH2201-203 NCT02643550	Innate Pharma	Recurrent or Metastatic HNSCC, post IO and/or platinum or naive	140	Dose Escalation (post plat) • Monalizumab + cetuximab Expansion cohort 1 (post IO/plat), 2 (naive) • Monalizumab + cetuximab Expansion cohort 3 (naive) • Monalizumab + cetuximab + durvalumab	Primary endpoints: • Occurrence of Dose Limiting Toxicities • Objective Response Rate Secondary endpoints: • ORR, DoR, PFS, OS
Phase 2 UPSTREAM NCT03088059	EORTC	Recurrent or Metastatic after first line platinum-based chemotherapy HNSCC	340	Arm B1 to B6: see Biomarker-based Study in R/M HNSCC - Full Text View - ClinicalTrials.gov Arm I1 (PD(L)-1 naïve or resistant) • Monalizumab monotherapy Arm I2 (PD(L)1 pretreated) • Monalizumab + durvalumab or SoC	Primary endpoints: • Progression Free Survival Rate • Objective Response Rate Secondary endpoints: • PFS, RR, RD, OS, Toxicity...

Monalizumab (NKG2A mAb): NSCLC

Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 2 NeoCOAST NCT03794544	AstraZeneca	Resectable early stage (I to IIIA) NSCLC	80	Arm 1: • Neoadjuvant durvalumab monotherapy Arm 2: • Neoadjuvant durvalumab with novel agents including monalizumab	Primary endpoints: • Major Path. Resp Rate Secondary endpoints: • Feasibility to surgery, AE, CR, PK, immunogenicity
Phase 2 NeoCOAST-2 NCT05061550	AstraZeneca	Resectable early stage (II to IIIA) NSCLC	140	Arm 1: • Durvalumab + Oleclumab + chemotherapy Arm 2: • Durvalumab + Monalizumab + chemotherapy	Primary endpoints: • pathological Complete Response (pCR) • Adverse Events and Serious Adverse Events Secondary endpoints: • EFS, DFS, surg. res., mPR, ORR, OS, Ser con., ADA, baseline PD-L1 exp., ctDNA
Phase 3 (Planned) COAST	AstraZeneca	Unresectable (stage III) NSCLC	TBD	TBD	TBD
Phase 2 PIONeer NCT03833440	AP-HM	Advanced stage or recurrent NSCLC	120	Arm 1: • Durvalumab + monalizumab Arm 2: • Durvalumab + MEDI9447 Arm 3: • Durvalumab + ADF6748 Arm 4: • Docetaxel	Primary endpoints: • 12-week Disease Control Rate Secondary endpoints: • ORR, PFS, OS, DoR

Monalizumab (NKG2A mAb): others

Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 1/2 D419NC00001 NCT02671435	AstraZeneca	Advanced solid tumours	381	Escalation phase - Monalizumab + durvalumab Expansion phase - Monalizumab + durvalumab Exploration phase - Durvalumab +monalizumab + SoC with or without biologic agent	Primary endpoints: - Safety - Exploration Phase: Objectivs Response per RECIST Secondary endpoints: - OR, DC, DoR, PFS, OS, immunogenicity, PK, PD
Phase 1 PIRAT NCT02921685	Institut Paoli-Calmettes	Hematologic Malignancies	18	Arm 1: Monalizumab monotherapy	Primary endpoints: - Occurrence of Dose Limiting Toxicities Secondary endpoints: - Incidence of acute GVHD - NRM, DFS, OS

Lacutamab (KIR3DL2 mAb)

Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 2 TELLOMAK NCT03902184	Innate Pharma	R/R Sezary Syndrome Stage IB-IV Mycosis Fungoides	Up to 150	Cohort 1: R/R Sezary Syndrome • Lacutamab monotherapy Cohort 2: Mycosis Fungoides KIR3DL2+ • Lacutamab Monotherapy Cohort 3: Mycosis Fungoides, KIR3DL2- • Lacutamab Monotherapy	Primary endpoints: • Objective Response Rate Secondary endpoints: • AE, QoL, PFS, OS, DoR, Immunogenicity, PD, PK
Phase 2 KILT NCT04984837	LYSA	R/R Peripheral T Cell Lymphoma	56	Arm 1: • Lacutamab + GEMOX Arm 2: • GEMOX	Primary endpoints: • Median modified Progression-Free Survival Secondary endpoints: • AE, OS, CRR, DoR, Immunogenicity, PD, PK
Phase 1b (Planned)	Innate Pharma	R/R Peripheral T Cell Lymphoma	TBD	Monotherapy Lacutamab	TBD

IPH6101/SAR443579 (CD123/NKp46/CD16a)

Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 1/2 NCT05086315	Sanofi	B-cell Acute Lymphoid Leukemia High Risk-Myelodisplasia	82	Arm 1: • Dose Escalation: SAR443579 administered intravenously at escalating dose levels. • Dose Expansion: SAR443579 administered intravenously at the recommended dose and schedule determined from the dose escalation.	Primary endpoints: • Incidence of dose-limiting toxicity (DLT) • Proportion of participants who have a CR (Complete Remission) + CRi (Complete Remission with Incomplete Hematological Recovery) Secondary endpoints: • Recommended Phase 2 dose • Treatment-emergent adverse events • Cmax, AUC0-T • Incidence of anti-drug antibody • Anti-leukemic activity • Proportion of participants with CR, CRh, Cri, MLFS • Time interval from first documented evidence of CR until PD • Time interval from date of first administration to induction failure, relapse or death • Proportion of survivors from the first administration to death • Rate of HSCT • Time from first administration to discontinuation excluding remission

Adenosine Pathway

Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 1 IPH5201 (CD39) NCT04261075	AstraZeneca	Advanced Solid Tumors	204	Dose escalation - IPH5201 monotherapy Dose escalation - IPH5201 + durvalumab Dose escalation - IPH5201 + durvalumab + oleclumab	Primary endpoints: - Adverse effect - Clinically significant laboratory values as a measure of safety - ECG abnormalities Secondary endpoints: - OR, DC, Half-life of IPH5201, Cmax, AUC, immunogenicity
Phase 1 (Planned) IPH5301 (CD73)	Innate Pharma	TBD	TBD	TBD	TBD

Avdoralimab (C5aR1 mAb)



Trials	Sponsor	Population	Patients	Design	Endpoints
Phase 2 NCT04563923	CHU Nice	Bullous Pemphigoid	40	Arm 1: • Avdoralimab + Clobetasol proprionate cream Arm 2: • Clobetasol proprionate cream	Primary endpoints: • Complete Clinical Remission Secondary endpoints: • Delay • Initial Clinical Remission